Skip to main content
Clinical Trials/CTRI/2017/02/007886
CTRI/2017/02/007886
Completed
Phase 4

A comparative study of efficacy and safety of Duloxetine 40mg vs Duloxetine 60mg in patients with taxane induced peripheral neuropathy.

Mysore Medical College and Research Institute0 sites44 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Taxane induced peripheral neuropathy
Sponsor
Mysore Medical College and Research Institute
Enrollment
44
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
June 5, 2018
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Mysore Medical College and Research Institute

Eligibility Criteria

Inclusion Criteria

  • 1\)Age \> 18 years of age.
  • 2\)All patients who received Paclitaxel 175mg/m2 and should have developed peripheral neuropathy due to paclitaxel.
  • 3\)Had \> grade 1 sensory CIPN based on NCI Common Toxicity Criteria for Adverse Events (CTCAE) V.4\.0\. grading scale.
  • 4\)Patients with any cancer diagnosis or stage .
  • 5\)No precedent peripheral neuropathy.

Exclusion Criteria

  • Participants with a documented medical history of
  • 1\)Preceding neuropathy due to Diabetes mellitus.
  • 2\)Neuropathy from any other type of nerve compression ( eg. Carpal / tarsal tunnel syndrome, radiculopathy , spinal stenosis, brachial plexopathy).
  • 3\)Severe depression.
  • 4\)Suicidal ideation.
  • 5\)Bipolar disorder.
  • 6\)Alcohol abuse.
  • 7\)Markedly abnormal renal or liver function test.

Outcomes

Primary Outcomes

Not specified

Similar Trials